Her-2/Neu IHC (breast)
Alternative name:
HER2
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
breast, ovarian, bladder, pancreatic, and stomach cancers
Measures the amount of HER2/neu protein on cancer cells or how many copies of the HER2/neu gene are in the DNA of cancer cells . The HER2/neu protein helps control normal cell growth. HER2 amplification/overexpression may be made seen in some cancers. About 20 percent of breast cancers are HER2-positive. HER2 positive cancers tend to grow and spread faster than other types of breast cancers. But treatments that specifically target HER2-positive breast cancer can be very effective. IHC should be used as the first screening method for HER2 evaluation and those cases with results considered equivocal for HER2 overexpression (2+) should be referred for FISH analysis or other alternative in situ hybridization method
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed for extended periods
Storage & Transport
Room Temperature
CPT(s)
88360
New York Approved
YES
TAT
1 Day
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
